Dr. Mark Tann, M.D.
Nuclear Medicine (Nuclear Radiology Physician)
- Medicare participating
At a glance
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nuclear Radiology Physician primary
IN license 01056509A -
Diagnostic Radiology Physician
IN license 01056509A -
Nuclear Imaging & Therapy Physician
IN license 01056509A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Indiana University Health Indianapolis, IN
- Indiana University Health Bloomington Hospital Bloomington, IN
- Indiana University Health Ball Memorial Hospital Muncie, IN
- Indiana University Health North Hospital Carmel, IN
- Cameron Health Angola, IN
Medical groups
- Iu Health Medical Group LLC (4,462 clinicians)
- Indiana University Radiology Associates Inc (178 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,007
- Services billed
- 1,195
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Nuclear medicine study from skull base to mid-thigh with ct scan | 618 | 561 |
| Nuclear medicine study whole body with ct scan | 130 | 118 |
| Radioactive drug therapy through a vein | 127 | 71 |
| Nuclear medicine study of bone and/or joint whole body | 91 | 79 |
| Dxa bone density measurement of hip, pelvis, spine | 75 | 75 |
| Nuclear medicine study of parathyroid with spect and ct scan | 41 | 40 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 32 | 32 |
| Nuclear medicine study of lung ventilation and circulation | 30 | 30 |
| Nuclear medicine study of liver and bile duct system | 29 | 29 |
| Nuclear medicine study of stomach to assess emptying | 29 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 1 companies reported 4 payments worth $94.36 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $94.36 |
|---|
| Food and Beverage | $94.36 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $147,051 in research payments for these studies, mostly to the institutions running them.
- A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Beigene, Ltd. · Active, not recruiting · NCT05100862 - Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy
Gilead Sciences, Inc. - A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Beigene, Ltd. · Active, not recruiting · NCT05952037
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.